Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

BACKGROUND: At time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered to be immediately operable (i.e. resectable). Considering their poor overall survival (OS), only tumours without vascular invasion (NCCN 2017) should be considered for resection, i.e. th...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Lilian, Vernerey, Dewi, Bachet, Jean-Baptiste, Tuech, Jean-Jacques, Portales, Fabienne, Michel, Pierre, Cunha, Antonio Sa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057099/
https://www.ncbi.nlm.nih.gov/pubmed/30041614
http://dx.doi.org/10.1186/s12885-018-4663-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057099/
https://www.ncbi.nlm.nih.gov/pubmed/30041614
http://dx.doi.org/10.1186/s12885-018-4663-4

Ejemplares similares